Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Liabilities (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Total Liabilities for 14 consecutive years, with $7.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities rose 45.25% year-over-year to $7.3 million, compared with a TTM value of $7.3 million through Sep 2025, up 45.25%, and an annual FY2024 reading of $7.1 million, up 14.99% over the prior year.
  • Total Liabilities was $7.3 million for Q3 2025 at Sunshine Biopharma, up from $6.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $7.6 million in Q4 2022 and bottomed at $95234.0 in Q1 2022.
  • Average Total Liabilities over 5 years is $4.7 million, with a median of $5.7 million recorded in 2023.
  • The sharpest move saw Total Liabilities crashed 96.76% in 2022, then soared 7840.3% in 2023.
  • Year by year, Total Liabilities stood at $2.0 million in 2021, then soared by 282.49% to $7.6 million in 2022, then dropped by 19.39% to $6.1 million in 2023, then rose by 14.99% to $7.1 million in 2024, then rose by 3.24% to $7.3 million in 2025.
  • Business Quant data shows Total Liabilities for SBFM at $7.3 million in Q3 2025, $6.3 million in Q2 2025, and $6.5 million in Q1 2025.